What are the recommended dosing regimens and monitoring parameters for calcineurin inhibitors (cyclosporine, tacrolimus, voclosporin, pimecrolimus) in adult solid‑organ transplantation, steroid‑dependent nephrotic syndrome, and atopic dermatitis?

Calcineurin Inhibitor Dosing and Monitoring

Solid Organ Transplantation

For adult kidney, liver, and heart transplant recipients, tacrolimus is the preferred calcineurin inhibitor over cyclosporine, initiated with specific weight-based dosing and therapeutic drug monitoring targeting whole blood trough concentrations. 1

Tacrolimus Dosing (First-Line Agent)

Kidney Transplantation:

• With azathioprine: 0.2 mg/kg/day divided every 12 hours
  • Target trough: 7-20 ng/mL (months 1-3), then 5-15 ng/mL (months 4-12)
• With MMF/IL-2 receptor antagonist: 0.1 mg/kg/day divided every 12 hours
  • Target trough: 4-11 ng/mL (months 1-12)
• Critical timing: May initiate within 24 hours post-transplant, but delay until renal function recovers 2

Liver Transplantation:

• 0.10-0.15 mg/kg/day divided every 12 hours
• Target trough: 5-20 ng/mL (months 1-12)
• Critical timing: No sooner than 6 hours after transplantation 2

Heart Transplantation:

• 0.075 mg/kg/day divided every 12 hours (with azathioprine or MMF)
• Target trough: 10-20 ng/mL (months 1-3), then 5-15 ng/mL (month ≥4)
• Critical timing: No sooner than 6 hours after transplantation 2

Race-Based Dosing Adjustments

African-American patients require approximately 30-50% higher tacrolimus doses to achieve comparable trough concentrations versus Caucasian patients. At 12 months post-transplant, African-American patients averaged 0.19 mg/kg/day versus 0.13 mg/kg/day for Caucasians to maintain therapeutic levels 2.

Cyclosporine Dosing (Alternative Agent)

When tacrolimus is contraindicated or not tolerated:

• Kidney transplant: 5 mg/kg/day divided every 12 hours initially
• Target trough: 50-100 µg/L 3
• Critical drug interaction: Never use cyclosporine simultaneously with tacrolimus; discontinue one agent at least 24 hours before initiating the other 2

Monitoring Requirements

Therapeutic drug monitoring is mandatory for all patients receiving calcineurin inhibitors 2:

• Measure trough concentrations at least twice weekly initially (daily if dose >10 mg/kg/day)
• Continue frequent monitoring until concentrations stabilize within target range
• Consider AUC monitoring for tacrolimus in rapid metabolizers who may experience higher peak concentrations and toxicities despite therapeutic trough levels 4

Renal function monitoring:

• Measure formal GFR every 2-3 years during CNI therapy
• Perform renal biopsy every 2-3 years to assess for CNI nephrotoxicity 5

Critical Drug Interactions

• Avoid grapefruit/grapefruit juice: Affects CNI metabolism 2, 3
• Strong CYP3A4/P-glycoprotein inhibitors: Significantly increase CNI levels, requiring dose reduction 6
• Mycophenolate: Standard adjunct therapy; does not require dose adjustment of CNI 1

---

Steroid-Dependent Nephrotic Syndrome

For severe steroid-dependent nephrotic syndrome in adults, tacrolimus at 0.1 mg/kg/day targeting trough levels of 5-10 µg/L provides steroid-sparing immunosuppression, though cyclosporine remains an alternative.

Tacrolimus Protocol

• Initial dose: 0.1 mg/kg/day divided every 12 hours
• Target trough: 5-10 µg/L
• Monitor for glucose intolerance and hypertension as limiting toxicities 5

Cyclosporine Alternative

• Initial dose: 5 mg/kg/day divided every 12 hours
• Target trough: 50-100 µg/L
• Evidence shows similar relapse rates between tacrolimus and cyclosporine (1 vs 2 relapses/year respectively), though neither demonstrates clear superiority 5

Important caveat: Both agents carry risk of CNI nephrotoxicity. Monitor GFR closely; mild histological nephrotoxicity may develop despite therapeutic drug levels during prolonged therapy 5.

---

Atopic Dermatitis

For adults with refractory moderate-to-severe atopic dermatitis, cyclosporine 3-5 mg/kg/day is conditionally recommended for limited-term use (up to 1 year maximum), with proper monitoring. 7

Cyclosporine Dosing (Off-Label)

• Initial dose: 3-5 mg/kg/day divided every 12 hours
• Duration limit: Maximum 1 year continuous use (based on FDA approval for psoriasis) 7
• Clinical improvement typically occurs within 2 weeks; satisfactory control may take 12-16 weeks 3
• Once controlled, taper to lowest effective maintenance dose 3

Topical Calcineurin Inhibitors (Pimecrolimus/Tacrolimus)

• Effective for long-term management and prophylaxis of atopic dermatitis
• Useful alternative to topical corticosteroids without steroid-related side effects
• Safety concerns regarding lymphoma/skin cancer have not been confirmed but remain under observation 8

Monitoring for Cyclosporine in Atopic Dermatitis

• Baseline and ongoing: Serum creatinine, blood pressure
• Dose reduction (25-50%) required if:
  • Serum creatinine increases ≥25% above baseline
  • Hypertension develops
  • Clinically significant laboratory abnormalities occur
• Discontinue if: Dose reduction ineffective or adverse events severe 3

Critical limitation: Cyclosporine is not FDA-approved for atopic dermatitis; comorbidities or drug interactions that may exacerbate toxicity make this intervention inappropriate for select patients 7.

---

Universal Precautions Across All Indications

Administration Guidelines

• Take consistently with or without food (if with food, same way each time)
• Avoid grapefruit products entirely
• Immediate-release and extended-release formulations are NOT interchangeable 2

Common Pitfalls

• Nephrotoxicity: All CNIs cause dose-dependent renal injury; long-term use is a major cause of chronic allograft dysfunction 1
• Infection risk: Increased susceptibility to opportunistic infections, particularly CMV 1
• Malignancy risk: Nonspecific increased cancer risk with chronic immunosuppression 1
• Neurotoxicity: Monitor for tremor, headache, seizures (particularly with tacrolimus)
• Metabolic effects: Hyperglycemia (tacrolimus > cyclosporine), hyperuricemia, hyperlipidemia 9